Eisai To Establish U.K. Facility To Take Drugs From R&D To Market
This article was originally published in PharmAsia News
Executive Summary
Eisai is opening a facility in the United Kingdom to take drugs from research through marketing, its first production base in Europe. The $165 million site is intended to more than double the company's drug researchers, to 60, and focus on developing drugs to treat mental ailments such as dementia. In a change from outsourcing its work to Europe, Eisai has decided to use a U.K. location to do research and develop, produce drugs and market them. Eisai expects to begin packaging drugs in the current fiscal year and produce pills and powders in fiscal 2010 with a capacity of producing 400 million pills a year. (Click here for more - a subscription may be required
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.